|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01XE04
|
|
gptkbp:brand
|
gptkb:Sutent
|
|
gptkbp:CASNumber
|
gptkb:557795-19-4
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
|
|
gptkbp:chemicalFormula
|
C22H27FN4O2
|
|
gptkbp:color
|
gptkb:orange
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
40-60 hours
|
|
gptkbp:form
|
capsule
|
|
gptkbp:genericName
|
gptkb:sunitinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sutent
|
|
gptkbp:indication
|
gptkb:advanced_renal_cell_carcinoma
imatinib-resistant GIST
progressive, well-differentiated pancreatic neuroendocrine tumors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:pregnancyRisk
|
positive evidence of risk
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
nausea
diarrhea
fatigue
hypertension
|
|
gptkbp:target
|
gptkb:PDGFR
gptkb:VEGFR
gptkb:KIT
gptkb:FLT3
gptkb:RET
|
|
gptkbp:usedFor
|
gptkb:gastrointestinal_stromal_tumor
gptkb:pancreatic_neuroendocrine_tumors
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:sunitinib
gptkb:DB01234
|
|
gptkbp:bfsLayer
|
7
|